Takeda announced a multiyear, large‑value partnership to integrate Iambic’s AI discovery platform into its small‑molecule R&D efforts across oncology, gastrointestinal and inflammation targets. The deal—reported with headline figures around $1.7 billion in potential value—aims to accelerate target ID and lead optimization using advanced computational tools. Takeda framed the agreement as part of a broader strategy to embed AI across discovery pipelines; Iambic gains resources and a partner to scale its models. The transaction exemplifies continued strategic licensing and AI partnerships as big pharma seeks to shorten lead timelines and diversify discovery funnels.